Clinical TrialMay 7, 2026, 07:02 AM
Aclaris ATI-052 Phase 1a Exceeds Target; Cash Runway to 2028
AI Summary
Aclaris Therapeutics announced positive full top-line results from its Phase 1a SAD/MAD trial of ATI-052, an investigational bispecific antibody, confirming its potential for best-in-class potency and extended dosing up to every three months. The company also reported its first-quarter 2026 financial results, including a net loss of $19.8 million and total revenue of $2.0 million. Aclaris expects its cash, cash equivalents, and marketable securities of $190.8 million to fund operations through the end of 2028, supporting its pipeline development, including planned Phase 2b trials for ATI-052 and ATI-2138.
Key Highlights
- ATI-052 Phase 1a trial showed potential best-in-class PK/PD profile, supporting up to every three-month dosing.
- Cash, cash equivalents, and marketable securities totaled $190.8 million as of March 31, 2026.
- Cash runway is expected to fund operations through the end of 2028.
- Q1 2026 net loss was $19.8 million, compared to $15.1 million in Q1 2025.
- Q1 2026 total revenue was $2.0 million, up from $1.5 million in Q1 2025.
- Q1 2026 R&D expenses increased to $15.7 million from $11.6 million in Q1 2025.
- Plans to initiate ATI-052 Phase 2b in Q4 2026 and ATI-2138 Phase 2b in H2 2026.
- Expects top-line results for ATI-052 Phase 1b and bosakitug Phase 2 in H2 2026/Q4 2026.